N-(5-氧代-5,6,7,8-四氢萘酚-2-基)乙酰胺 | 88611-67-0

• 物质功能分类: 化学试剂 - 有机试剂 - 酰胺
• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: N-(5-氧代-5,6,7,8-四氢萘酚-2-基)乙酰胺
• 中文别名: N1-(5-氧-5,6,7,8-四氢萘酚-2-基)乙酰胺；6-乙酰氨基-1,2,3,4-四氢萘-1-酮
• 英文名称: 6-acetamido-1,2,3,4-tetrahydronaphthalen-1-one
• 英文别名: 6-acetamido-1-tetralone；N-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide；N-(5-oxo-7,8-dihydro-6H-naphthalen-2-yl)acetamide
• CAS: 88611-67-0
• 化学式: C₁₂H₁₃NO₂
• mdl: MFCD00099461
• 分子量: 203.241
• InChiKey: WEBCZGJWXXPNHB-UHFFFAOYSA-N

物化性质

• 熔点：
  127 °C
• 沸点：
  439.6±34.0 °C(Predicted)
• 密度：
  1.225±0.06 g/cm3(Predicted)
• 溶解度：
  30.2 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S24/25
• 危险类别码：
  R22
• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温且干燥

SDS

Name:	N1-(5-oxo-5 6 7 8-tetrahydronaphthalen-2-yl)acetamide Material Safety Data Sheet
Synonym:
CAS:	88611-67-0

Section 1 - Chemical Product MSDS Name:N1-(5-oxo-5 6 7 8-tetrahydronaphthalen-2-yl)acetamide Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
88611-67-0	N1-(5-Oxo-5,6,7,8-tetrahydronaphthalen	>97%	unlisted

Hazard Symbols: XN
Risk Phrases: 22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 88611-67-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 124 - 126 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H13NO2
Molecular Weight: 203

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, acids, bases.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 88611-67-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
N1-(5-Oxo-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 88611-67-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 88611-67-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 88611-67-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-(5-氧代-5,6,7,8-四氢萘酚-2-基)乙酰胺 在 盐酸 、 乙酸酐 作用下， 以 甲醇 、 水 、 丙酮 为溶剂， 反应 2.16h， 生成 (6-acetamido-1-oxo-1,2,3,4-tetrahydronaphth-2-yl)acetonitrile
  参考文献：
  名称：

  Inotropic, vasodilator and low Km, cAMP-selective, cGMP-inhibited phosphodiesterase (PDE III) inhibitory activities of 4a-methyl-4,4a-dihydro-5H-indeno[1,2-c]pyridazin-3(2H)-ones and 4a-methyl-4,4a,5,6-tetrahydrobenzo[h]cinnolin-3(2H)-ones

  摘要：

  Novel 7-substituted-4,4a-dihydro-4a-methyl-5H-indenol[1,2-c]pyridazin-3[2H]-ones and 8-substituted-4a-methylbenzo[h]cinnolin-3[2H]-ones have been synthesized and their PDE III inhibitory, inotropic and vasodilator potencies compared with those of their normethyl analogues and their bicyclic 4,5-dihydro-6-phenylpyridazinone analogues. The structure-activity relationships of the tricyclic pyridazinones differ from those of bicyclic pyridazinones mainly in respect of the effect of introducing the methyl group into the pyridazinone ring. Whilst in the 4,5-dihydro-6-phenylpyridazin-3(2H)-ones, introduction of a 5-methyl group has been widely reported to lead to compounds of significantly greater potency, the novel tricyclic 4a-methylpyridazinones showed similar levels of inotropic, vasodilator and PDE III inhibitory potency to their normethyl analogues. Possible reasons for this difference in behaviour are discussed.

  DOI：

  10.1016/0223-5234(90)90196-a
• 作为产物：
  描述：

  3-(3-硝基苯甲酰基)丙酸 在 吡啶 、 aluminum (III) chloride 、 氯化亚砜 、 palladium 10% on activated carbon 、 氢气 、 溶剂黄146 作用下， 以 硝基甲烷 为溶剂， 20.0 ℃ 、400.01 kPa 条件下， 反应 9.5h， 生成 N-(5-氧代-5,6,7,8-四氢萘酚-2-基)乙酰胺
  参考文献：
  名称：

  Discovery, synthesis, and structure–activity relationship of 6-aminomethyl-7,8-dihydronaphthalenes as human melanin-concentrating hormone receptor 1 antagonists

  摘要：

  Human melanin-concentrating hormone receptor 1 (hMCHR1) antagonists are promising targets for obesity treatment. We identified the tetrahydronaphthalene derivative 1a with modest binding affinity for hMCHR1 by screening an in-house G protein-coupled receptor (GPCR) ligand library. We synthesized a series of 6-aminomethyl-5,6,7,8-tetrahydronaphthalenes and evaluated their activity as hMCHR1 antagonists. Modification of the biphenylcarbonylamino group revealed that the biphenyl moiety played a crucial role in the interaction of the antagonist with the receptor. The stereoselective effect of the chiral center on binding affinity generated the novel 6-aminomethyl-7,8-dihydronaphthalene scaffold without a chiral center. Optimization of the amino group led to the identification of a potent antagonist 2s (4'-fluoro-N[6-(1-pyrrolidinylmethyl)-7,8-dihydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide), which significantly inhibited the nocturnal food intake in rats after oral administration. Pharmacokinetic analysis confirmed that 2s had good oral bioavailability and brain penetrance. This antagonist appears to be a viable lead compound that can be used to develop a promising therapy for obesity. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.07.038

文献信息

• [EN] NOVEL AMINOTETRALINE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS<br/>[FR] NOUVEAUX COMPOSES AMINOTETRALINE UTILES POUR SOIGNER LES TROUBLES ASSOCIES AU RECEPTEUR MCH
  申请人：7TM PHARMA AS

  公开号：WO2003087046A1

  公开（公告）日：2003-10-23

  Novel compounds of formula (I) which modulate MCH activity are disclosed in which A is a linker; Ar1 is an aryl or heteroaryl group; R1 and R2 are hydrogen, straight or branched alkyl, alkenyl or alkynyl groups, cycloalkyl groups, alkylcycloalkyl groups, alkylaryl groups, alkylheterocyclyl groups, alkylheteroaryl groups and may be linked to each other; R3 is a hydrogen atom, Alk-, Alk-O-, hydroxy or keto group; R4 and R5 are hydrogen, halogen atoms, alkoxy groups, hydroxy, alkylamino groups, dialkylamino groups, hydroxylalkyl groups, carboxamido groups, acylamido groups, acyl groups, -CHO, nitrile, alkyl, alkenyl or alkynyl groups, -CF3, -OCF3, -SCF3; -SCH3, -SO2NH2, -SO2NHAlk, -SO2Nalk2, -SO2Alk; n is 1 or 2; R8 is halogen atoms, alkyl, alkenyl or alkynyl groups, cycloalkyl groups with 3-7 carbons, alkylcycloalkyl groups, alkylaryl groups, alkylheterocyclyl groups, heteroaryloxyl groups, alkylheteroaryl groups, arylalkoxy groups, aryloxy groups, alkoxy groups, dialkylamino groups, -CONHAlk, -CONHAr, -CONAlk2, -NHCO-Alk, -NHCO-Ar, -CO-Alk, -CO-Ar, -SCH3, -CF3, -OCF3, -SCF3; or R8 is R6-Ar2-B-; in which B is a connecting moiety; Ar2 is an aryl or heteroaryl group; R6 is an R5 group; and which are useful in the treatment or prevention of e.g. obesity, depression, diabetes, bulimia etc.

  化合物的新结构式（I），其调节MCH活性的方法已被披露，其中A是一个连接物；Ar1是芳基或杂环芳基；R1和R2是氢、直链或支链烷基、烯基或炔基、环烷基、烷基环烷基、烷基芳基、烷基杂环烷基、烷基杂芳基，它们之间可能相互连接；R3是氢原子、烷基、烷氧基、羟基或酮基；R4和R5是氢、卤素原子、烷氧基、羟基、烷基氨基、二烷基氨基、羟基烷基、羧酰胺基、酰胺基、酰基、-CHO、腈基、烷基、烯基或炔基、-CF3、-OCF3、-SCF3、-SCH3、-SO2NH2、-SO2NHAlk、-SO2Nalk2、-SO2Alk；n为1或2；R8是卤素原子、烷基、烯基或炔基、含有3-7个碳的环烷基、烷基环烷基、烷基芳基、烷基杂环烷基、杂芳氧基、烷基杂芳基、芳基烷氧基、芳氧基、烷氧基、二烷基氨基、-CONHAlk、-CONHAr、-CONAlk2、-NHCO-Alk、-NHCO-Ar、-CO-Alk、-CO-Ar、-SCH3、-CF3、-OCF3、-SCF3；或R8是R6-Ar2-B-；其中B是连接基；Ar2是芳基或杂环芳基；R6是一个R5基团；这些化合物在治疗或预防肥胖、抑郁症、糖尿病、暴食症等方面是有用的。
• Practical Synthesis of (3a<i>R</i>, 9b<i>R</i>)-8-Fluoro-7-(perfluoropropan-2-yl)-9b-(phenylsulfonyl)-2,3,3a,4,5,9b-hexahydro-1<i>H</i>-benzo[e]indole: An Advanced Intermediate to Access the RORγt Inverse Agonist <b>BMT-362265</b>
  作者：Ananta Karmakar、Roshan Y. Nimje、Arundutt Silamkoti、Manivel Pitchai、Mushkin Basha、Christuraj Singarayer、Duraisamy Ramasamy、G. T. Venkatesh Babu、Ramesh Samikannu、Srinath Subramaniam、Prakash Anjanappa、Muthalagu Vetrichelvan、Hemantha Kumar、Amol G. Dikundwar、Anuradha Gupta、Arun Kumar Gupta、Richard Rampulla、T. G. Murali Dhar、Arvind Mathur

  DOI：10.1021/acs.oprd.1c00019

  日期：2021.4.16

  uoropropan-2-yl)-9b-(phenylsulfonyl)-2,3,3a,4,5,9b-hexahydro-1H-benzo[e]indole 10, an advanced intermediate en route to the synthesis of the RORγt inverse agonist, BMT-362265, is described starting from fluorobenzene. The synthesis involved the screening of multiple synthetic routes for their feasibility and scalability. We also demonstrate the utility of an annulating reagent, (R)-N-(2-chloroethy

  一种实用且可扩展的方法，可制得（3a R，9b R）-8-氟-7-（全氟丙烷-2-基）-9b-（苯磺酰基）-2,3,3a，4,5,9b-六氢-1 H从氟苯开始描述了-苯并[e]吲哚10，它是合成RORγt反向激动剂BMT-362265的高级中间体。合成涉及针对其可行性和可扩展性筛选多种合成路线。我们还证明了在多克规模上用于三环吡咯烷中间体24和36的非对映选择性合成的成环剂（R）-N-（2-氯乙基）-2-甲基丙烷-2-亚磺酰胺的实用性。
• Melanin concentrating hormone antagonist
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07115750B1

  公开（公告）日：2006-10-03

  A melanin-concentrating hormone antagonist which comprises a compound of the formula: wherein Ar1 is a cyclic group which may have substituents; X is a spacer having a main chain of 1 to 6 atoms; Y is a bond or a spacer having a main chain of 1 to 6 atoms; Ar is a monocyclic aromatic ring which may be condensed with a 4 to 8 membered non-aromatic ring, and may have further substituents; R1 and R2 are independently hydrogen atom or a hydrocarbon group which may have substituents; R1 and R2, together with the adjacent nitrogen atom, may form a nitrogen-containing hetero ring which may have substituents; R2 may form a spiro ring together with Ar; or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing hetero ring which may have substituents; or a salt thereof; which is useful as an agent for preventing or treating obesity, etc.

  一种黑色素浓缩激素拮抗剂，包括以下式的化合物： 其中Ar1是可能具有取代基团的环状基团； X是具有1到6个原子的主链的间隔物； Y是键或具有1到6个原子的主链的间隔物； Ar是可能与4到8个成员的非芳香环融合的单环芳香环，并且可能具有进一步的取代基团； R1和R2分别是氢原子或可能具有取代基团的碳氢基团；R1和R2，连同相邻的氮原子，可能形成可能具有取代基团的含氮杂环；R2可能与Ar一起形成螺环；或者R2，连同相邻的氮原子和Y，可能形成可能具有取代基团的含氮杂环；或其盐； 该化合物可用作预防或治疗肥胖等疾病的药剂。
• HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：EP3782995A1

  公开（公告）日：2021-02-24

  The present invention relates to a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the treatment of various HAT-related diseases or conditions.

  本发明涉及一种组蛋白乙酰转移酶（HAT）抑制剂。提供了一种由通式I表示的化合物，其药学上可接受的盐，立体异构体，对映异构体，顺反异构体，对映异构体，消旋体，多晶型，溶剂合物或其同位素标记化合物（包括氘取代），以及其制备方法，包含相同的药物组成，以及在治疗各种HAT相关疾病或症状中的用途。
• Amine compounds, their production and use as amyloid-&bgr; production inhibitors
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06310107B1

  公开（公告）日：2001-10-30

  A compound of the formula: wherein Ar is an aromatic ring assembly group which may be substituted or a fused aromatic group which may be substituted; X is (i) a bond, (ii) —S—, —SO— or —SO2—, (iii) C1-6 alkylene, C2-6 alkenylene or C2-6 alkynylene, etc., (iv) —CO—O— or (v) —(CH2)p-X1—, —(CH2)p-X1— (CH2)q-, —(CH2)r-CO—X1—, —SO2—NR8— or —(CH2)r-SO2—NR8— wherein X1 is O or NR8, R8 is H, a hydrocarbon group which may be substituted or an acyl, p is 0 to 5, q is 1 to 5, p+q is 1 to 5, and r is 1 to 4; Y is a divalent C1-6 aliphatic hydrocarbon group optionally containing O or S, which may be substituted; R1 and R2 each is H or a lower alkyl which may be substituted, or R1 and R2 form a N-containing heterocyclic ring which may be substituted; Ring A is a benzene ring which may be further substituted; and Ring B is a 4- to 8-membered ring which may be further substituted, or a salt thereof has the effect of inhibiting amyloid-&bgr; protein production and/or secretion and is useful as a pharmaceutical composition for preventing and/or treating the neurodegenerative disease, etc.

  该化合物的化学式如下：其中Ar是一种芳香环组合基团，可以是取代的或者是取代的融合芳香基团；X是（i）一个键，（ii）—S—，—SO—或—SO2—，（iii）C1-6烷基，C2-6烯基或C2-6炔基等，（iv）—CO—O—或（v）—（CH2）p-X1—，—（CH2）p-X1—（CH2）q-，—（CH2）r-CO—X1—，—SO2—NR8—或—（CH2）r-SO2—NR8—其中X1是O或NR8，R8是H，一个可以被取代的碳氢基团或酰基，p是0到5，q是1到5，p+q是1到5，r是1到4；Y是一个二价的C1-6脂肪烃基，可选含有O或S，可以是取代的；R1和R2分别是H或一个可以被取代的较低烷基，或者R1和R2形成一个可以被取代的含氮杂环；环A是一个苯环，可以进一步被取代；环B是一个4至8元环，可以进一步被取代，或其盐具有抑制淀粉样蛋白β蛋白的产生和/或分泌的作用，并且可作为预防和/或治疗神经退行性疾病等的药物组成部分。